Nexalin Technology, Inc. Stock: price and insider trades · United States

In competitive terms, Nexalin remains a specialized and relatively early-stage player rather than a scaled commercial medtech platform. Its differentiation rests on intellectual property, peer-reviewed clinical publications, and regulatory engagement with the U.S. FDA. The company seeks to position its DIFS technology as a more evidence-based and deeper-acting alternative to more superficial neurostimulation approaches, and it has highlighted U.S. patent protection in substance-use disorder applications as an important strategic asset. ([nexalin.com](https://nexalin.com/nexalin-highlights-its-expanding-body-of-peer-reviewed-neuroimaging-research-confirming-its-difs-technology-as-the-leader-in-evidenced-based-non-invasive-brain-stimulation/?utm_source=openai))

Geographically, Nexalin’s principal executive offices are in Houston, Texas, while investor relations and transfer-agent support are managed through New York. The company’s communications also point to international activity, including leadership meetings in both the U.S. and China, suggesting that expansion potential is not limited to the domestic market. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001527352/000182912626002673/nexalintech_10k.htm?utm_source=openai))

Recent developments have been central to the investment case. During 2025 and 2026, Nexalin reported additional positive clinical data in Alzheimer’s disease, published peer-reviewed results across multiple indications, advanced a pivotal trial for HALO™ Clarity, secured USPTO patent coverage for substance-use disorders, and completed phases one through five of its virtual clinic and digital ecosystem. At the same time, the company’s 2025 annual report states that it has incurred significant losses and has substantial doubt about its ability to continue as a going concern, underscoring the importance of capital access and execution risk for investors. ([nexalin.com](https://nexalin.com/nexalin-technology-announces-completion-of-phases-one-through-five-of-its-virtual-clinic-and-digital-ecosystem-for-halo-clinical-research-and-patient-management/?utm_source=openai))